Wockhardt share price gains 14% on DCGI approval for 2 new antibiotics
16 January 2020
Wockhardt share price gained 14 percent intraday on January 16 after the pharma company received Indian regulatory approval for its two new antibiotics.
The Drug Controller General of India (DCGI) approved EMROK (IV) and EMROK 0 (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections, and concurrent bacteraemia.
Further reading: MoneyControl
Author(s): MoneyControl
Healthy Patients Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
